CMBI assisted Hansoh Pharma in successfully listing on the Main Board of Hong Kong Stock Exchange

June 14th, 2019, Hansoh Pharmaceutical Group Company Limited (“Hansoh Pharma” or the “Company”) (stock code: 3692.HK) successfully listed on Hong Kong stock exchange main board. CMBI acted as Joint Lead Manager for Hansoh Pharma’s IPO.

Hansoh Pharma is one of the few R&D-driven Chinese pharmaceutical companies with an established leadership position in some of the largest and fastest-growing therapeutic areas in China with significant unmet clinical needs. Hansoh Pharma has a broad, diversified and leading drug portfolio in (i) central nervous system (“CNS”) diseases, (ii) oncology, (iii) anti-infectives, and (iv) diabetes. Hansoh Pharma also focuses on the gastrointestinal and cardiovascular therapeutic areas. Together, these six therapeutic areas accounted for 62.5% of the total sales revenue of pharmaceuticals in China in 2018 and grew faster than the Chinese pharmaceutical industry as a whole, which grew at 8.1% on average from 2014 to 2018.

Hansoh Pharma issued 551,280,000 new shares in the global offering and was priced at HK$14.26 per share, with total proceeds being HK$7,861 million (assuming Over-Allotment Option is not exercised). The book was multiple times covered with a good mixed of investors. The international offering was oversubscribed because of the Company's excellent fundamentals and attractive pricing level.

As the joint lead manager in this project, CMBI played an important role in deal execution, marketing and sales. Leveraging strong network of Chinese investors, high net-worth individuals, CMBI assisted the Company in introducing many long-term, high quality and low price-sensitive investors, which has made an important contribution to successful listing of Hansoh Pharma.

About Hansoh Pharma

Hansoh Pharma is one of the few R&D-driven Chinese pharmaceutical companies with an established leadership position in some of the largest and fastest-growing therapeutic areas in China with significant unmet clinical needs. Hansoh Pharma has a broad, diversified and leading drug portfolio in (i) central nervous system (“CNS”) diseases, (ii) oncology, (iii) anti-infectives, and (iv) diabetes. Hansoh Pharma also focuses on the gastrointestinal and cardiovascular therapeutic areas. Together, these six therapeutic areas accounted for 62.5% of the total sales revenue of pharmaceuticals in China in 2018 and grew faster than the Chinese pharmaceutical industry as a whole, which grew at 8.1% on average from 2014 to 2018.

Company’s diversified product portfolio includes eight main products with established market-leading positions and track record, which the Company refer to as its core products, and five other main products launched more recently with strong growth potential. These thirteen main products accounted for 83.4%, 85.7% and 89.5% of the Company’s revenue in 2016, 2017 and 2018, respectively. Most of these products are in the CNS diseases, oncology, anti-infectives and diabetes areas, the four therapeutic areas the Company strategically targets. In addition, the Company has one main product in the gastrointestinal area. Among Company’s main products, Mailingda is a Category 1.1 innovative drug, Oulanning, Ameining, Pulaile, Zefei, Xinwei, Xintai, Zetan, Hengjie, Hengsen, Fulaidi and Ruibote are first-to-market generic drugs, and Xinmei is a generic drug. Furthermore, the Company targets to launch nearly 30 drug candidates from 2019 to 2020, including 15 drug candidates that the Company thinks have high growth potential, which comprise four candidates of Category 1.1 innovative drugs with NMEs and eight potential first-to-market generic drugs. As of the date of this document, the Company launched four of these 15 drug candidates between December 2018 to May 2019, including one Category 1.1 innovative drug, polyethylene glycol loxenatide, launched in May 2019. The Company’s broad and diversified portfolio and pipeline ensure its ability to withstand market and regulatory changes and maintain a strong financial growth trajectory.

Publish Date:2019-06-13
BackHome

Address: 45th & 46th Floor, Champion Tower, 3 Garden Road, Central, Hong Kong

Telephone: (852)3900 0888 Fax:(852)3761 8788

Copyright © 2019-2024 CMB International Capital Corporation Limited. All rights reserved.